A Phase II Study of AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety
4 weeks
Yes
United States: Food and Drug Administration
AVN944-006
NCT00493441
June 2007
December 2009
Name | Location |
---|---|
University of Nebraska Medical Center | Omaha, Nebraska 68198-3330 |
Arizona Clinical Research Center | Tucson, Arizona 85712 |
Columbia University | New York, New York 10032-3784 |
Yale University | New Haven, Connecticut 06520 |
California Pacific Medical Center Research Institute | San Francisco, California 94115 |
Virginia Cancer Institute | Richmond, Virginia 23230 |
Chattanooga Oncology and Hematology Associates | Chattanooga, Tennessee 37404 |
Emory University - Winship Cancer Institute | Atlanta, Georgia 30322-1013 |
University of Tennessee Medical Center | Knoxville, Tennessee 37920 |
Hematology Oncology Associates of Rockland | Nyack, New York 10960 |
University of Southern California - Norris Comprehensive Cancer Center | Los Angeles, California 90033 |
Georgetown University, Lombardi Comprehensive Cancer Center | Washington, District of Columbia 20007 |
University of Florida - Shands Cancer Center | Gainesville, Florida 32610 |
Joliet Oncology and Hematology Associates | Joliet, Illinois 60435 |
Cleveland Clinic - Taussig Cancer Center | Cleveland, Ohio 44195 |
Sarah Cannon Research Institute -Tennessee Oncology | Nashville, Tennessee 37203 |